These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25477188)

  • 1. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan.
    Tung YC; Lin YS; Wu LS; Chang CJ; Chu PH
    J Clin Hypertens (Greenwich); 2015 Jan; 17(1):51-8. PubMed ID: 25477188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O; Andrews LM; Wang L; Xie L
    J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
    Ferrario CM; Panjabi S; Buzinec P; Swindle JP
    Ther Adv Cardiovasc Dis; 2013 Feb; 7(1):27-39. PubMed ID: 23328188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.
    Dickson M; Plauschinat CA
    Am J Cardiovasc Drugs; 2008; 8(1):45-50. PubMed ID: 18303937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
    da Silva PM
    Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension.
    Kumagai N; Onishi K; Hoshino K; Nakamori S; Kitai T; Yazu T; Oota M; Ueda Y; Hiraoka N; Okamoto S; Yamada T; Dohi K; Nakamura M; Ito M
    Clin Exp Hypertens; 2013; 35(5):355-60. PubMed ID: 23072348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
    Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy.
    Malesker MA; Hilleman DE
    Manag Care; 2010 Jul; 19(7):36-42. PubMed ID: 20672530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
    Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy for hypertension: focus on a single-pill fixed-dose combination of valsartan and amlodipine.
    Miura S; Saku K
    J Int Med Res; 2012; 40(1):1-9. PubMed ID: 22429340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amlodipine and valsartan as components of a rational and effective fixed-dose combination.
    Waeber B; Ruilope LM
    Vasc Health Risk Manag; 2009; 5(1):165-74. PubMed ID: 19436661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.
    Hsiao FC; Tung YC; Chou SH; Wu LS; Lin CP; Wang CL; Lin YS; Chang CJ; Chu PH
    Medicine (Baltimore); 2015 Dec; 94(51):e2355. PubMed ID: 26705234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    Yamashita K; Kondo T; Muramatsu T; Matsushita K; Nagahiro T; Maeda K; Shintani S; Murohara T
    Am J Cardiol; 2013 Dec; 112(11):1750-6. PubMed ID: 24035165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
    Koyanagi R; Hagiwara N; Yamaguchi J; Kawada-Watanabe E; Haruta S; Takagi A; Ogawa H;
    J Cardiol; 2013 Oct; 62(4):217-23. PubMed ID: 23778009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
    Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
    Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [One-year persistence of fixed-dose combinations of angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertensive patients].
    Simonyi G; Ferenci T; Finta E; Igaz I; Balogh S; Gasparics R; Medvegy M
    Orv Hetil; 2019 Mar; 160(9):343-348. PubMed ID: 30798621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake.
    Toyoda S; Inami S; Kato T; Tsukada K; Nakamoto A; Kikegawa Y; Suzuki A; Anraku Y; Node K; Inoue T
    Am J Med Sci; 2015 Sep; 350(3):160-6. PubMed ID: 26196407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability.
    Ulusoy S; Ozkan G; Konca C; Kaynar K
    Hypertens Res; 2012 Nov; 35(11):1111-7. PubMed ID: 22786565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.